The recent earnings conference call revealed strong sales performance for Amgen's products in the second quarter of the year. The sales increased by 2% year-over-year, with notable growth in sales outside the U.S. The key financial metrics highlighted in the call include the performance of specific products such as Prolia, KYPROLIS, XGEVA, Nplate, Vectibix, Neulasta, NEUPOGEN, Enbrel, Aranesp, Sensipar, and Repatha. 

Prolia, a product for post-menopausal osteoporosis, saw sales increase by 15% with an 18% volume growth, globally distributed among regions. KYPROLIS experienced 23% year-over-year growth and had positive overall survival data in multiple myeloma patients. XGEVA, Nplate, and Vectibix also saw strong volume growth. However, there was a decline in sales for NEUPOGEN and Enbrel. Aranesp and Sensipar both showed growth, mostly due to volume and net selling prices. Repatha also demonstrated steady market leadership with a 58% share of the PCSK9 segment in the U.S. and Europe.

The discussion also covered inventory management and changes in net selling prices affecting sales performance. Additionally, the company is focused on accessing new markets and expanding the patient population for its products. 

There was also discussion around the potential pricing and market access for Aimovig, a new product for treating migraine. The company highlighted its engagement with payers and efforts to improve patient access. The call also referred to the importance of outcomes data for Repatha and ongoing work with payers to improve access to the drug.

Overall, the call highlighted Amgen's efforts to address the needs of patients and physicians, and the company's focus on pricing, market access, and market share growth for its products.